Apogee Therapeutics Overview
Apogee Therapeutics Target Price
Analysts' average 12-month price target for Apogee Therapeutics is $130.
Get informed when a big investor buys or sells
+ FollowShare Price
$135.07
Average Target Price
$130.28
3.5% downside
3.5% downside8 analysts in the last 4 months
High: $135.11 | Low: $97
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-08-13 | Truist Financial | $135 | 0.1% downside |  |
| 2026-06-24 | Stifel Nicolaus | $135 | 0.1% downside | |
| 2026-06-24 | Mizuho SecuritiesJoseph Catanzaro | $135 | 0.1% downside | |
| 2026-06-23 | RBC Capital | $135 | 0.1% downside | |
| 2026-06-23 | UBS | $135.11 |  0% upside | |
| 2026-06-22 | Deutsche BankDavid Hoang | $135 | 0.1% downside | |
| 2026-06-22 | Craig-Hallum | $135.11 | 0% upside | |
| 2026-06-08 | RBC CapitalBrian Abrahams | $97 | 28.2% downside | |
| 2026-05-28 | Goldman Sachs | $89 | 34.1% downside | |
| 2026-05-27 | Truist FinancialDanielle Brill | $81 | 40% downside | |
| 2026-05-27 | Wedbush | $135 | 0.1% downside | |
| 2026-05-01 | Redburn PartnersQize Ding | $140 | 3.6% upside | |
| 2026-03-17 | Truist FinancialDanielle Brill | $83 | 38.6% downside | |
| 2026-02-02 | JefferiesAkash Tewari | $95 | 29.7% downside | |
| 2026-01-22 | RBC Capital | $83 | 38.6% downside | |
| 2026-01-07 | Craig-Hallum | $116 | 14.1% downside | |
| 2026-01-06 | BTIG | $137 | 1.4% upside | |
| 2026-01-06 | Stifel Nicolaus | $133 | 1.5% downside | |
| 2025-12-16 | Stephens | $95 | 29.7% downside | |
| 2025-12-09 | Deutsche Bank | $103 | 23.7% downside | |
| 2025-11-03 | Craig-Hallum | $109 | 19.3% downside | |
| 2025-09-25 | RBC Capital | $60 | 55.6% downside | |
| 2024-05-13 | Stifel NicolausAlex Thompson | $95 | 29.7% downside | |